Between 1998 and 2012, 101 Alzheimer’s drug development projects were halted or became inactive. In that time three new medicines have been approved to treat the symptoms of Alzheimer’s disease – so-called “failed” projects outnumber approved medicines 34 to 1.
Setbacks are an inherent part of discovering and testing new medicines. In the face of these deeply disappointing setbacks, researchers take the findings from the unsuccessful projects and use them to inform the next step forward and continue to explore new research avenues, building on knowledge gained from prior research. Biopharmaceutical researchers and the companies they work for are committed to finding treatments that realize the promise of our expanding scientific knowledge to halt or prevent the disease.Download